RALYL and hepatocellular carcinoma: Overexpression of RALYL suppressed the m6A level of TGF-β2 mRNA to enhance its mRNA stability, leading to subsequent activation of TGF-β signaling that contributed to HCC self-renewal and chemoresistance (Wang et al., 2021).